Ocular Therapeutix, Inc. (OCUL)

Price$8.25

Value ScoreD

Growth ScoreC

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-40.02%

Price vs S&P 500 (4W)-14.50%

VGM Score38.20

Market Capitalization$1.81B

All Metrics

Book Value / Share (Quarterly)$2.66

P/TBV (Annual)5.03x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)0.30%

Cash Flow / Share (Quarterly)$-1.10

Price vs S&P 500 (YTD)-40.20%

Gross Margin (TTM)87.24%

Net Profit Margin (TTM)-558.24%

EPS (TTM)$-1.46

10-Day Avg Trading Volume2.28M

EPS Excl Extra (TTM)$-1.46

Revenue Growth (5Y)24.45%

EPS (Annual)$-1.42

ROI (Annual)-36.65%

Gross Margin (Annual)87.35%

Net Profit Margin (5Y Avg)-221.35%

Cash / Share (Quarterly)$3.05

Revenue Growth QoQ (YoY)0.81%

ROA (Last FY)-32.91%

Revenue Growth TTM (YoY)-12.66%

EBITD / Share (TTM)$-1.47

ROE (5Y Avg)-79.74%

Operating Margin (TTM)-575.42%

Cash Flow / Share (Annual)$-1.00

P/B Ratio3.11x

P/B Ratio (Quarterly)3.17x

Net Income / Employee (Annual)$-818,300

EV / Revenue (TTM)23.29x

Net Interest Coverage (TTM)-5.44x

ROA (TTM)-48.36%

EPS Incl Extra (Annual)$-1.42

Current Ratio (Annual)15.39x

Quick Ratio (Quarterly)14.49x

3-Month Avg Trading Volume4.78M

52-Week Price Return-2.48%

Revenue / Employee (TTM)$160,100

Tangible BV / Share (Quarterly)$0.10

P/S Ratio (Annual)34.77x

Asset Turnover (Annual)0.06x

52-Week High$16.44

Operating Margin (5Y Avg)-256.39%

EPS Excl Extra (Annual)$-1.42

CapEx CAGR (5Y)70.24%

Tangible BV CAGR (5Y)6.23%

26-Week Price Return-32.10%

Quick Ratio (Annual)15.11x

13-Week Price Return-20.14%

Total Debt / Equity (Annual)0.11x

Current Ratio (Quarterly)14.81x

Enterprise Value$1.21B

Revenue / Share Growth (5Y)-0.63%

Asset Turnover (TTM)0.09x

Book Value / Share Growth (5Y)24.79%

Revenue / Employee (Annual)$159,800

Inventory Turnover (Annual)1.99x

Pretax Margin (Annual)-511.90%

Cash / Share (Annual)$3.41

3-Month Return Std Dev64.80%

Gross Margin (5Y Avg)90.11%

Net Income / Employee (TTM)$-893,800

ROE (Last FY)-40.64%

Net Interest Coverage (Annual)-189.25x

EPS Basic Excl Extra (Annual)$-1.42

Receivables Turnover (TTM)2.10x

Total Debt / Equity (Quarterly)0.12x

EPS Incl Extra (TTM)$-1.46

Receivables Turnover (Annual)1.65x

ROI (TTM)-55.76%

P/S Ratio (TTM)34.71x

Pretax Margin (5Y Avg)-221.35%

Revenue / Share (Annual)$0.28

Tangible BV / Share (Annual)$0.46

Price vs S&P 500 (52W)-26.85%

Year-to-Date Return-32.04%

5-Day Price Return-7.61%

EPS Normalized (Annual)$-1.42

ROA (5Y Avg)-31.60%

Net Profit Margin (Annual)-511.90%

Month-to-Date Return-8.44%

Cash Flow / Share (TTM)$-0.83

EBITD / Share (Annual)$-1.42

Operating Margin (Annual)-519.75%

LT Debt / Equity (Annual)0.11x

ROI (5Y Avg)-43.97%

LT Debt / Equity (Quarterly)0.12x

EPS Basic Excl Extra (TTM)$-1.46

P/TBV (Quarterly)22.65x

P/B Ratio (Annual)3.95x

Inventory Turnover (TTM)1.90x

Pretax Margin (TTM)-558.24%

Book Value / Share (Annual)$3.03

Price vs S&P 500 (13W)-28.39%

Beta0.93x

Revenue / Share (TTM)$0.23

ROE (TTM)-64.55%

52-Week Low$6.23

vGradeD

gGradeC

mGradeD

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.40est. -0.32

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.32

4.28

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
OCULOcular Therapeutix, Inc.	D	C	D	$8.25
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Ocular Therapeutix is a biotechnology company developing innovative eye disease treatments using its proprietary hydrogel platform technology, which enables improved therapeutic delivery compared to traditional eye drops. The company's pipeline includes multiple product candidates across various ophthalmic indications, including the FDA-approved Dextenza. Its platform technology addresses key limitations of conventional eye-drop therapies, positioning the company to capture market share in large ophthalmic disease markets.